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 Personal Narrative 
 
Original parts: Aging and reckoning with cystic fibrosis related kidney 
disease 
Alexandra CH Nowakowski, PhD, MPH, Florida State University College of Medicine, xnowakowski@fsu.edu 
 
 
Abstract 
Kidney disease increasingly impacts people with cystic fibrosis (CF) as adult patients continue to survive longer. Yet the 
literature on CF related kidney disease focuses little on amplifying the voices of people aging with the condition. This 
article presents perspectives on CF related kidney disease from a medical sociologist who is themselves managing these 
issues. It (1) gives an overview of relevant literature and trends in epidemiological data on kidney disease and CF, (2) 
details the author’s own process of adjusting to progressive changes in renal function, and (3) outlines opportunities for 
clinicians to make a positive impact for patients by centering their voices. 
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Introduction 
 
My kidneys and I recently celebrated 34 years of life—a 
milestone that might have seemed unrealistic had I been 
born in a different time. It seemed out of reach for me as 
well until I began getting coordinated care for my cystic 
fibrosis (CF), a disease that has likewise spent all 34 years 
with me but only received proper management well into 
my adult years. CF is a genetic disease in which the body 
cannot produce, transport, and/or use a specific type of 
protein that helps electrolytes get across cell membranes1. 
It remains the most common fatal genetic disease among 
people of European heritage2. Surviving and beginning to 
thrive with my CF has thus involved reckoning with many 
things beyond my own mortality as a general construct. 
Like any other patient, I constantly engage in illness 
management—the process of adjusting to changes in my 
health and allowing them to become part of my sense of 
normalcy3. And like any other scientist, I generally begin 
my processes of reckoning by examining data. In this 
narrative, I use my experiences to (1) give an overview of 
scholarship related to CF and kidney disease, (2) detail my 
experiences managing CF and kidney disease, and (3) 
outline ways clinicians can better serve patients by 
amplifying our voices.  
 
An Overview of Scholarship on CF and Kidney 
Disease 
 
Throughout my 34 years and counting, some trends in CF 
survival data have remained remarkably similar. Over 80 
percent of people with CF still die from respiratory failure, 
even if they live for many decades before their lungs 
eventually succumb to the ravages of the disease4. That 
leaves the other 20 percent of us who will likely still die 
from our CF, but from impacts to other organ systems as 
opposed to steep declines in lung function5. Kidney 
disease increasingly ranks among the leading causes of 
death for adults with CF6. This represents a change in the 
data from the early 1980s when I was born. My 
nephrologist here in Orlando commented that the learning 
curve for physicians has been just as steep as it has for 
patients with respect to chronic kidney disease, as only 
recently did people with CF begin surviving long enough 
in sufficient numbers to present a substantial case 
population. 
 
Kidney disease is not a universal experience among people 
with CF, in part because so many patients continue to 
experience respiratory failure. The unique form of diabetes 
associated with CF can also harm the kidneys, but is 
observed in under 50 percent of the total disease 
population7. Likewise, not everyone who does develop CF 
related diabetes experiences kidney dysfunction as a 
result8. However, every person living with CF does 
experience elevated risk for renal impairment, especially as 
they grow older9. Several factors can contribute to kidney 
disease in people aging with CF. One prominent factor is 
obstruction of the glomeruli—the small ducts inside of the 
kidneys that transport fluids—with hardened pieces of 
mucus10. While I return to other pieces of CF or kidney 
disease where relevant later in the piece, these examples 
represent the overall picture of the intersection of these 
conditions in the existing scholarship. With this 
background in mind, I now shift to my own experiences 
before drawing on those experiences to make suggestions 
for clinicians in closing.  
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My Experience with CF and Kidney Disease 
 
Years before my pulmonologist would ask how all my 
doctors in New Jersey never recognized these “casts” in 
my urine for what they were, I would stand beneath the 
lighting fixture in my parents’ kitchen as we all peered at a 
jam jar full of my urine. My mother and father, with PhDs 
in neuroscience and cell biology respectively and a 
collective four decades of experience as medical educators, 
were just as mystified as I was by the glowing white 
threads that floated in the liquid. Although we all spared a 
moment to appreciate the humor of collecting a urine 
specimen in a dainty little gingham-topped jar, there was 
also a sense of foreboding. Two years prior, I had been 
admitted to intensive care with a tentative diagnosis of 
renal failure. 
 
Further testing—including the singularly peculiar 
experience of collecting all of my urine and feces for 24 
hours while trying not to trip over my intravenous pole or 
drop my heart monitor into the toilet—revealed that my 
kidneys were stressed but responding as best they could to 
problems with other systems. The next time I was able to 
speak to my mother, who had frantically offered to give 
me one of her kidneys as my father haggled with airline 
ticket agents, I told her to keep her organs for the time 
being. With a serum potassium of 2.1 milliequivalents per 
liter that refused to budge even after oral supplements 
were introduced on top of the IV, I found humor where I 
could. But the laughter faded quickly as it became clear 
that the specter of kidney disease had long since become 
reality. 
 
I spent years shuttling around to various nephrologists, 
first in central New Jersey and then in northern Florida as 
my increasing intolerance to cold drove me southward. 
Raynaud’s syndrome manifested early—a consequence of 
the vascular damage increasingly seen in adults with CF as 
survival increases11. I wound up in Orlando, where care 
options for adults with CF are markedly better, through a 
combination of persistence and serendipity when FSU 
College of Medicine offered me a transfer to the Regional 
Campus here in exchange for my commitment to build out 
our community partnerships for aging research in the area. 
I enthusiastically accepted what amounted to a dream 
come true with no small sense of the irony inherent in it—
someone with what remains a decidedly terminal illness 
leading research efforts centered around healthy aging. Yet 
that became an important milestone in my adaptation to 
living with the impacts of my CF, which at that point had 
been diagnosed conclusively, initiating a good deal of 
scrambling by myself and a vast team of clinicians to 
compensate for lost time. 
 
Indeed, one of the other common causes of kidney 
damage in people with CF contributed strongly to the 
conversion of my diagnosis from a lifelong suspicion to a 
formal pronouncement. I moved down to Orlando with a 
raging bacterial infection that had spread through my 
entire renal and urinary system. Such infections often 
spiral out of control in people whose CF is inadequately 
managed, as mine was for the better part of three decades. 
Paradoxically, some of the more aggressive drug therapies 
used for CF can also make the kidneys more vulnerable to 
bacterial colonization12. I fell victim to this truism as well 
when ranitidine, a medication intended to reduce my 
gastrointestinal symptoms, aggravated my kidney issues so 
much that my entire lower body broke out in vasculitis 
rashes. A quick literature search revealed that vascular 
complications associated with kidney inflammation tend to 
occur more often in CF patients with substantial 
autoimmunity13 as already documented in my own medical 
records. I showed up at my primary care doctor’s office in 
Tallahassee, passed him a series of pictures on my phone, 
and said “I have Henoch-Schoenlein purpura”. Although 
this was far from a good day, it paved the way for much 
better ones to follow. 
 
Months later, my new nephrologist would gently diagnose 
me with chronic kidney disease—“but only Stage 1, we still 
have plenty of time”—and send me off for a 
comprehensive renal and urinary ultrasound. While I 
waited for the results, I spent a lot of time thinking back to 
that day in the hospital when I told my mother to keep her 
kidneys, and all the times we had argued since about 
whether or not I should list for a transplant if my own 
failed. I thought about my pulmonlogist’s confidence that 
by a combination of atypical genetics and hard work, I 
might survive long enough for my CF to become largely 
irrelevant for my life expectancy. Combing through 
endless arrays of literature and data, I concluded that 
although this was an outcome I very much wanted for 
myself and my family, getting there might require difficult 
decisions about my willingness to consider organ 
transplantation.  
 
This meant that I needed types of data that are often more 
difficult to find in research journals—those that amplify 
patient voices and experiences14. I knew plenty of people 
with double lung transplants, something that had never 
been on the table for me once inhaled corticosteroids had 
rescued my pulmonary function15. As I got more involved 
in the CF community online, I also came to know several 
people who had undergone successful kidney transplants. 
Some of them even had stories like mine—relatively 
classic phenotypic cases of CF that fell through the cracks 
in a broken health care system. My first chloride sweat 
tests, once the gold standard for diagnosing CF, were 
performed at a scant few years of age. Insufficient sweat 
meant no conclusive diagnosis despite concerning results, 
and I floundered into adulthood with a halfway managed 
disease playing havoc with my body. I lost upwards of 40 
pounds from my slender frame that I would never find 
again. I lived with chronic mycobacterial pneumonia for 
Cystic fibrosis related kidney disease, Nowakowski 
  
 
 
Patient Experience Journal, Volume 5, Issue 1 – 2018 9 
most of my 20s. My kidneys screamed with pain daily. My 
legs swelled, the skin shining and painful with edema; my 
eyes bulged from my skull. I began to think about dialysis 
not as a question of “if” but rather one of “when”. 
 
Yet things slowly began to improve. Some of the news I 
received was bad, if not unexpected—the kidney disease 
diagnosis, the evidence of thickened airways, the near-total 
failure of my pancreas to produce digestive enzymes 
anymore. Other pieces of news were better—airways only 
mildly thickened, lung function good and increasing, no 
diabetes despite the exocrine pancreatic insufficiency, 
kidney disease present but not progressing. I learned how 
to manage my kidney health better—not drinking 
inordinate quantities of water, managing my thirst instead 
with a combination of good hydration practices and 
mucus-thinning drugs, getting my medications adjusted to 
avoid adverse reactions, starting on special vitamin 
supplements for people with CF, staying away from 
anything that could damage the blood vessels further.  
 
As I felt the seeds of empowerment taking root, I thought 
about the stories I had heard from friends online—people 
living happily with their transplanted kidneys, free from 
dialysis and the misery of waiting between sessions. I 
thought doubly hard about my mantra from all those 
years—“I’ll manage”—and wondered if perhaps that was 
an appropriate way of thinking now that I was no longer 
dying of a mysterious disease but rather living with a 
reasonably well understood one. I moved the goalpost 
accordingly—to be the oldest living person with CF, 
botched diagnosis and fragmented care be damned. I had 
learned that my genetics were not only atypical, but also 
likely to mean that I only had problems using the CF 
transmembrane conductance regulator protein rather than 
producing or transporting it, which likely meant my 
prognosis was better than those of many of my peers. 
 
When the results from my renal ultrasound came back, I 
thought about those too. My nephrologist gave me a 
hopeful smile for the first time, saying that there was no 
severe damage to the tubules or other structures in my 
kidneys—just widespread inflammation and some light 
scarring. And as we continued to monitor my renal 
bloodwork and urine output, he said that my kidney 
disease did not appear to be progressing at a rapid rate. I 
contemplated the possibility of finishing out this life with 
all of my original parts, save the multiple teeth I had 
already lost and the gum tissue that had to be surgically 
reconstructed after its destruction by years of chronic 
infections. I still do not know if that hope will become 
reality for me, but I realized recently that I have come to a 
place in my life and health care where I can accept either 
alternative. I shared that with my parents in a lengthy 
series of text messages as if it were a small matter. Yet they 
knew, as I did, the seismic shift it represented in my 
thinking about the future. 
Advice for Clinicians Serving Patients with CF 
and Kidney Disease 
 
I share my experience now to highlight the importance of 
centering patient voices in care for kidney disease, whether 
related to CF or otherwise. Many people resist even 
discussing organ transplantation as an option because they 
have not gotten the opportunity to hear from recipients of 
successful donations16. Transplant can seem like an 
incredibly fatalistic prospect, especially for people who 
already know they are living with terminal diseases. The 
fact that your condition may take a very long time to kill 
you does not, I have learned, take away the fear that comes 
with thinking about potential kidney failure. I always said 
that I was not afraid to die, but rather afraid to suffer; that 
statement remains true for me today. I also still get regular 
tastes of the suffering my CF can induce with respect to 
renal function, from the recurrent infections that turn my 
urine cloudy and foul to the shooting pains from 
inflammation and temporary obstructions in the ducts. 
 
Yet I have learned to think differently about suffering 
itself, in terms of both the potential for a successful 
physical outcome and the likelihood of emotional value 
being gained by allowing the person who gave me life to 
continue giving to me in that way. Perhaps most 
importantly, I have learned not to look at myself as a 
“waste” of any donated kidney I might receive, whether 
my mother’s or a deceased person’s, because of the 
progressive nature of my disease. After all, you do not get 
to be the oldest living person with CF without taking a few 
risks along the way—foremost among them opening your 
mind to things you thought you would never consider. As 
more adults with CF continue surviving into late life with 
each passing year, it will be increasingly critical for 
nephrology practitioners not only to understand the 
challenges we face with our kidney health, but to 
communicate with us about those struggles in ways that 
promote empowerment. Centering our voices in that 
dialogue offers a hugely impactful and readily achievable 
specific aim in support of that broader goal. 
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